Department of Clinical Pharmacy, Faculty of Pharmacy, University of Szeged, Szeged, Hungary.
Péterfy Sándor Street Hospital, Budapest, Hungary.
Diabet Med. 2019 Dec;36(12):1612-1620. doi: 10.1111/dme.14117. Epub 2019 Sep 9.
To analyse glucose-lowering drug utilization, focusing on the novel glucose-lowering drug groups dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors, and the financial burden they entail.
Crude reimbursed national drug utilization and expenditure data for the entire population of Hungary were obtained from the National Health Insurance Fund for the study period: 2008 to 2017. Data were analysed using the WHO's Anatomical Therapeutic Chemical Classification/defined daily dose system and were expressed in defined daily dose per 1000 inhabitants per day.
Total glucose-lowering drug consumption in Hungary showed an 18% increase over the study period, reaching 74.7 defined daily doses per 1000 inhabitants per day, while novel glucose-lowering drug use increased to 11.7 defined daily doses per 1000 inhabitants per day (16% of total glucose-lowering drug use) by 2017. Dipeptidyl-peptidase 4 inhibitor consumption grew to 7.4 defined daily doses per 1000 inhabitants per day by 2017. The most widely used dipeptidyl-peptidase 4 inhibitor was sitagliptin. Glucagon-like peptide-1 receptor agonists were used the least, but by 2017 rose to 1.5 defined daily doses per 1000 inhabitants per day, led by liraglutide. Sodium-glucose co-transporter-2 inhibitors appeared in the utilization data in 2014 and their consumption, mainly empagliflozin, reached 2.8 defined daily doses per 1000 inhabitants per day by 2017. The total expenditure on glucose-lowering drugs increased 94% between 2008 and 2017, and the total cost of novel glucose-lowering drug utilization comprised 44% of the total glucose-lowering drug expenditure in 2017.
Both the use of and the financial burden posed by novel glucose-lowering drugs in Hungary increased steadily between 2008 and 2017. This increase is expected to continue.
分析降糖药物的使用情况，重点关注新型降糖药物，即二肽基肽酶-4 抑制剂、胰高血糖素样肽-1 受体激动剂和钠-葡萄糖共转运蛋白-2 抑制剂，并评估其带来的经济负担。
从匈牙利国家健康保险基金获得研究期间（2008 年至 2017 年）全国人群的未调整的国家药品使用和支出数据。使用世界卫生组织（WHO）的解剖治疗化学分类/定义日剂量系统对数据进行分析，并以定义日剂量/每 1000 居民/天表示。
匈牙利的总降糖药物使用量在研究期间增长了 18%，达到 74.7 定义日剂量/每 1000 居民/天，而新型降糖药物的使用量在 2017 年增加到 11.7 定义日剂量/每 1000 居民/天（占总降糖药物使用量的 16%）。二肽基肽酶 4 抑制剂的使用量在 2017 年增长到 7.4 定义日剂量/每 1000 居民/天。使用最广泛的二肽基肽酶 4 抑制剂是西格列汀。胰高血糖素样肽-1 受体激动剂的使用量最少，但在 2017 年上升至 1.5 定义日剂量/每 1000 居民/天，主要是利拉鲁肽。钠-葡萄糖共转运蛋白-2 抑制剂于 2014 年出现在使用数据中，其主要药物恩格列净的使用量在 2017 年达到 2.8 定义日剂量/每 1000 居民/天。2008 年至 2017 年间，降糖药物总支出增长了 94%，2017 年新型降糖药物总费用占降糖药物总支出的 44%。
2008 年至 2017 年间，匈牙利新型降糖药物的使用和经济负担均稳步增长。预计这种增长将持续下去。
